CMPS•benzinga•
FDA Endorses CaaMTech's Psilocin Drug Development For Depression Treatment
Summary
FDA supports CaaMTech's CT-4201 psilocin program for depression, advancing psychedelic therapy and clearing key regulatory hurdles.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 14, 2024 by benzinga